We are pleased to announce that Arevipharma has received a CEP (Certificate of European Pharmacopoeia) for the active ingredient rivastigmine.

Rivastigmine is a well-established active ingredient used to treat symptoms of dementia associated with Alzheimer’s disease and Parkinson’s-related dementia. As a cholinesterase inhibitor, rivastigmine supports signal transmission in the brain and can help improve or preserve patients’ memory, thinking, and daily functioning for longer.

Receiving this CEP underscores Arevipharma’s commitment to the highest quality standards, regulatory excellence, and the reliable supply of high-quality active pharmaceutical ingredients to the global pharmaceutical market.